Artiva Biotherapeutics (ARTV) Treasury Shares (2023 - 2025)

Artiva Biotherapeutics (ARTV) has reported Treasury Shares for 4 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares fell 34.09% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (down 34.09% YoY), while the FY2025 annual figure was $2.6 million, up 421.07% from the prior year.
• Treasury Shares rose to $4.1 million in Q1 2026 per ARTV's latest filing, from $2.6 million in the prior quarter.
• Across five years, Treasury Shares topped out at $6.2 million in Q1 2025 and bottomed at $506845.0 in Q4 2024.
• Historically, Treasury Shares has averaged $3.5 million across 4 years, with a median of $3.7 million in 2023.
• Annual changes were most pronounced in 2024 — Treasury Shares sank 79.62% — and 2025, when it jumped 421.07%.
• Artiva Biotherapeutics' Treasury Shares stood at $2.5 million in 2023, then tumbled by 79.62% to $506845.0 in 2024, then surged by 421.07% to $2.6 million in 2025, then soared by 53.73% to $4.1 million in 2026.
• Business Quant data shows ARTV's Treasury Shares at $4.1 million in Q1 2026, $2.6 million in Q4 2025, and $6.2 million in Q3 2025.